Business Description
Acrivon Therapeutics Inc
NAICS : 541713
SIC : 2833
ISIN : US0048901096
Description
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 27.45 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -130.9 | |||||
| 3-Year EPS without NRI Growth Rate | -88.1 | |||||
| 3-Year FCF Growth Rate | -108.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.76 | |||||
| 9-Day RSI | 45.83 | |||||
| 14-Day RSI | 51.7 | |||||
| 6-1 Month Momentum % | 24.85 | |||||
| 12-1 Month Momentum % | -49.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.75 | |||||
| Quick Ratio | 9.75 | |||||
| Cash Ratio | 9.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.5 | |||||
| Shareholder Yield % | 0.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -40.83 | |||||
| ROA % | -37.7 | |||||
| ROIC % | -249.92 | |||||
| ROC (Joel Greenblatt) % | -990.04 | |||||
| ROCE % | -44.2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.57 | |||||
| Price-to-Tangible-Book | 1.57 | |||||
| EV-to-EBIT | -2.07 | |||||
| EV-to-Forward-EBIT | -1.51 | |||||
| EV-to-EBITDA | -2.08 | |||||
| EV-to-FCF | -3.16 | |||||
| Price-to-Net-Current-Asset-Value | 1.69 | |||||
| Price-to-Net-Cash | 1.73 | |||||
| Earnings Yield (Greenblatt) % | -48.31 | |||||
| FCF Yield % | -16.82 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ACRV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Acrivon Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.74 | ||
| Beta | 0 | ||
| Volatility % | 90.43 | ||
| 14-Day RSI | 51.7 | ||
| 14-Day ATR ($) | 1.202264 | ||
| 20-Day SMA ($) | 8.6385 | ||
| 12-1 Month Momentum % | -49.44 | ||
| 52-Week Range ($) | 3.19 - 14.3 | ||
| Shares Outstanding (Mil) | 30.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Acrivon Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Acrivon Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Acrivon Therapeutics Inc Frequently Asked Questions
What is Acrivon Therapeutics Inc(ACRV)'s stock price today?
The current price of ACRV is $8.46. The 52 week high of ACRV is $14.30 and 52 week low is $3.19.
When is next earnings date of Acrivon Therapeutics Inc(ACRV)?
The next earnings date of Acrivon Therapeutics Inc(ACRV) is 2024-05-09 Est..
Does Acrivon Therapeutics Inc(ACRV) pay dividends? If so, how much?
Acrivon Therapeutics Inc(ACRV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers